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Abstract
Background: In Brazil, lethality from visceral leishmaniasis (VL) is high and few studies have addressed prognostic factors.
This historical cohort study was designed to investigate the prognostic factors for death from VL in Belo Horizonte (Brazil).
Methodology: The analysis was based on data of the Reportable Disease Information System-SINAN (Brazilian Ministry of
Health) relating to the clinical manifestations of the disease. During the study period (2002–2009), the SINAN changed
platform from a Windows to a Net-version that differed with respect to some of the parameters collected. Multivariate
logistic regression models were performed to identify variables associated with death from VL, and these were included in
prognostic score.
Principal Findings: Model 1 (period 2002–2009; 111 deaths from VL and 777 cured patients) included the variables present
in both SINAN versions, whereas Model 2 (period 2007–2009; 49 deaths from VL and 327 cured patients) included variables
common to both SINAN versions plus the additional variables included in the Net version. In Model 1, the variables
significantly associated with a greater risk of death from VL were weakness (OR 2.9; 95%CI 1.3–6.4), Leishmania-HIV co-
infection (OR 2.4; 95%CI 1.2–4.8) and age $60 years (OR 2.5; 95%CI 1.5–4.3). In Model 2, the variables were bleeding (OR 3.5;
95%CI 1.2–10.3), other associated infections (OR 3.2; 95%CI 1.3–7.8), jaundice (OR 10.1; 95%CI 3.7–27.2) and age $60 years
(OR 3.1; 95%CI 1.4–7.1). The prognosis score was developed using the variables associated with death from VL of the latest
version of the SINAN (Model 2). The predictive performance of which was evaluated by sensitivity (71.4%), specificity
(73.7%), positive and negative predictive values (28.9% and 94.5%) and area under the receiver operating characteristic
curve (75.6%).
Conclusions: Knowledge regarding the factors associated with death from VL may improve clinical management of patients
and contribute to lower mortality.
Citation: de Arau ´jo VEM, Morais MHF, Reis IA, Rabello A, Carneiro M (2012) Early Clinical Manifestations Associated with Death from Visceral Leishmaniasis. PLoS
Negl Trop Dis 6(2): e1511. doi:10.1371/journal.pntd.0001511
Editor: Richard Reithinger, George Washington University, United States of America
Received September 8, 2011; Accepted December 21, 2011; Published February 7, 2012
Copyright:  2012 de Arau ´jo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by DECIT/MS/CNPq/BR/grant:576062/2008-1, PPSUS/MS/CNPq/FAPEMIG/SES-MG/grant: CDS-APQ-00343-10 and
FAPEMIG/PPM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mcarneir@icb.ufmg.br
Introduction
The number of new cases of visceral leishmaniasis (VL) is
estimated to be around 500,000 per year worldwide with over
50,000 deaths [1]. The majority (.90%) of cases is concentrated in
six countries, namely, Bangladesh, Brazil, Ethiopia, India, Nepal
and Sudan [2]. In Latin America, the causative agent of VL is the
intracellular protozoan Leishmania infantum (syn. L. chagasi) [3], and
the disease is systemic and characterized clinically by prolonged
fever, weight loss, hepatomegaly, splenomegaly, hypergammaglob-
ulinemia and pancytopenia. In the absence of treatment, the disease
may have fatal consequences [4]. Additionally, the susceptibility to
VL, and consequently the epidemiology of the disease, has been
influenced by the expansion of human immunodeficiency virus
(HIV) in South America, Asia and Africa. Indeed, of the 88
countriesthatareendemicforVL,35havealreadyreported casesof
Leishmania-HIV co-infection [5]. On this basis, VL is considered an
extremely serious public health problem [1,2].
In Brazil since the 1980’s the geographical distribution of VL
has expanded, partly due to increased urbanization [1,2,6–14]. In
the 1980s, an average of 1,500 cases was reported each year in
Brazil and between 2000–2009 the average increased to 3,480
cases annually, an increase of 132% [13].
In fact, between 1990 and 2009, a total of 57,973 clinical cases
of VL had been reported [13], representing 90% of all cases
notified in the American continent. These figures do not take into
account the unreported cases, which are not insignificant
[1,3,6,15,16].
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lance Program (VLCP) of Brazil [17] all suspected and confirmed
cases of VL must be notified to the sanitary authorities and
registered in the Reportable Disease Information System
(SINAN, Brazilian Ministry of Health). This system not only
provides a center for the collection and processing of data, but
also for the dissemination of information generated by the
epidemiological surveillance systems linked to the municipal, state
and federal governments. Moreover, the SINAN contributes to
the knowledge of morbimortality worldwide by VL, since it helps
make up the consolidated data from institutions such as PAHO
(Pan American Health Organization) and WHO (World Health
Organization).
The control of VL in urban areas of Brazil represents,
however, a difficult and continuous challenge despite the
measures adopted by the Brazilian Ministry of Health, and
implemented through of the VLCP [17], which emphasizes the
early diagnosis and treatment of clinical cases [18]. In most
countries, pentavalent antimonial drugs has been the first choice
treatment for more than 70 years [2]. Although more specific
guidelines for the management of patients suffering from severe
VL have been developed in Brazil [19], the case fatality rate
remains high [14]. In Belo Horizonte, the capital of the State of
Minas Gerais, the VLCP guidelines have been followed since
1993 but death from VL has not been reduced. In fact, during
the period 2002–2009 the case fatality rate of VL in Belo
Horizonte ranged from 8.2% (in 2007) to 22.0% (in 2009) with an
average of 12.6%, whilst the rate in the country was much lower
and varied between 5.6% (in 2008) and 8.5% (in 2003) with an
average of 7.0% [14].
Since reduction of case fatality rate is one of the goals of VLCP
[17], it is important to understand the determinants of such a
poor result in a metropolis presenting active transmission of L.
infantum [20]. Hence, the objective of the present study was to
investigate the early clinical manifestations associated with death
from VL using information available from the SINAN database
obtained at the moment of clinical case suspicion. Also a
prognostic clinical score was proposed to identify patients at a
higher risk of death.
Methods
Ethical statement
The study was approved by the Ethical Review Board of the
Universidade Federal de Minas Gerais (No.211/09) and of the
Municipality Health Service of Belo Horizonte (No.075.2008).
Data were analyzed anonymously.
Study design and population
The study was carried out in Belo Horizonte, the capital of the
State of Minas Gerais, located in southeastern Brazil, an area
comprising 2,375,444 inhabitants [21]. This historical cohort
study was based on secondary VL data from 2002 to 2009. Owing
to the prolonged incubation period of the disease, data for 2009
were only finalized in March 2010 and, hence, the complete set of
information for that year was not available at the time of the study.
Data were obtained from the Reportable Disease Information
System-SINAN (Brazilian Ministry of Health and Municipality
Health Service of Belo Horizonte) and complemented with data of
the Mortality Information System-SIM (Brazilian Ministry of
Health and Municipality Health Service of Belo Horizonte). The
selection criteria for inclusion in the study were: (i) the patient was
resident in Belo Horizonte; (ii) the patient represented a new case
of VL; (iii) the case was registered at SINAN, and, if appropriate,
(iv) the primary cause of death of the patient was VL. Based on
these criteria, 888 VL patients (92% of all of those registered) were
selected for the study and, of these, 111 died (88% of all deaths
from VL.
SINAN database
The epidemiological surveillance system of the Brazil involved
registration of the suspected VL case at SINAN using a form
comprising the following entries: date of notification, health unit
responsible for notification, address, age, sex, level of schooling,
occupation of patient, date of the start of symptoms and clinical
manifestations (signs and symptoms). Subsequently, further
information was added to the records including the results of
specific laboratory examinations, date of beginning of treatment,
initial drug used for treatment, drug used following failure of the
initial therapy, and evolution of the case.
The SINAN database changed platform during the study period
from a Windows-based version (2002–2006) to a Net version
(2007–2009). As shown in Table 1, the Net version contained
more information than the Windows version except for the field
relating to co-infections, which was simplified (HIV remained but
tuberculosis was removed). Of the 888 cases, 512 had been
registered in the Windows version and 376 in the Net version.
Data from the two versions of the SINAN database was combined
in order to create a single database, and the consistency of the data
contained therein evaluated. The variables analyzed in the present
study were sex and age of patient, clinical manifestations (signs and
symptoms), co-infections (HIV and tuberculosis), date of notifica-
tion, date of the onset of symptoms, initial drug administered,
duration of treatment with pentavalent antimonial drugs, other
drug administered following failure of initial therapy, evolution of
the case (cure or death from VL) and date of death (if applicable).
Those variables exhibiting high levels of missing information, such
as schooling (55.5%), ethnicity (51.8%), weight (83.8%), occupa-
tion (85.0%), date of the start of treatment (69.1%) and relapse
(86%) were excluded from the study.
Statistical analysis
Statistical analyses of the data were performed using STATA
version 11.0 software (Stata Corp., College Station, TX, USA)
Author Summary
The visceral leishmaniasis (VL) is a disease potentially fatal
if not diagnosed and treated opportunely. This article
presents the results of the study on the manifestations
identified at the time of the clinical suspicion of the VL
cases. This study was conducted in Belo Horizonte, the
capital of the State of Minas Gerais, located in southeast-
ern Brazil. This study is both timely and substantive
because the Belo Horizonte is an area of transmission of
VL, with one of the highest VL-death proportions of Brazil.
The patients with higher risk of death had at least one of
the following characteristics: $60 years, weakness, HIV co-
infection, bleeding, jaundice and other associated infec-
tions. During the period 2002–2009, 8% to 22% of the
patients with VL progressed to death in Belo Horizonte,
whilst the proportion in the country was much lower and
varied between 5% and 9%. This study has identified
vulnerable patients who are at higher risk of death from VL
and who would benefit from early predictive evaluation of
the prognostic. Hence, the knowledge regarding the
factors associated with death may contribute for clinical
management and for reduction of deaths from VL.
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Univariate logistic regression analysis was used to evaluate the
demographic and clinical variables according to the occurrence of
death from VL. Variables associated with death from VL at a
significance level of p,0.25, along with those previously
considered in the literature to be biologically important in the
occurrence of death from L. infantum, were included in multivariate
logistic regression analyses. Variables with more than two
categories were transformed into dummies variables.
Two multivariate logistic regression models were subsequently
analyzed. Model 1 covered the period 2002 to 2009 and included
the variables present in both versions of SINAN (111 deaths and
777 cured patients), whereas Model 2 covered the period 2007 to
2009 and included the variables common to both versions of
SINAN together with the new variables included in the Net
version (49 deaths and 327 cured patients). With the aim of
avoiding selection bias, and to allow better adjustment of the
model to VL data, the category ‘‘unknown’’ was maintained for
variables for which information was missing. Variables presenting
collinearity were evaluated and those that better explained the
occurrence of death from VL were retained in the model.
A step-by-step backward selection procedure was used to select
the variables and to produce the final multivariate logistic
regression models. Only adjusted variables showing a significant
association (p,0.05) with the occurrence of death from VL
remained in the final models. The strength of association was
determined by odds ratio at a 95% confidence interval.
The predictive factors relating to death from VL that were
identified by Model 2 (period 2007–2009) were used to create a
prognosis score. According to the methodology described by
Barquet et al. [22], the regression coefficient of each of the
variables was divided by the smallest coefficient and the quotient
was rounded to the nearest integer in order to facilitate the clinical
use of the system. The prognosis score was validated against all
cases registered during the period 2007–2009. The actual
evolution of each patient, defined as death from VL (yes versus
no), was compared with the predictive score. For the purposes of
comparison, patients attaining a predictive score in the range from
1 to 5 received an allocated score of 1, while those presenting none
of the death prognosis factors received an allocated score of 0. The
predictive performance of the score was determined by sensitivity,
specificity, positive and negative predictive values, and the area
under the receiver operating characteristic curve (ROC) [23].
Results
The incidence of VL in Belo Horizonte during the period 2002–
2009 varied from 3.4 to 6.6/100,000 inhabitants and the case
fatality rate was 13.1% (Table 2). The highest levels of lethality
were observed in 2009 (22.0%) followed by 2004 (18.7%). The
ages of the 888 VL subjects varied between 3 months and 93 years;
the ages of those that died from VL ranged from 5 months to 86
years (n=111; median=18 years; interquartile range=4241
years), whereas the ages of cured patients varied from 3 months to
93 years (n=777; median=32 years; interquartile range=7254
years). Case fatality rate amongst patients presenting Leishmania-
HIV co-infection was 17.7% (12/68), while lethality amongst those
with Leishmania-tuberculosis co-infection was 10.5% (4/38). Of the
nine patients presenting both types of co-infection (Leishmania-
HIV-tuberculosis), four progressed to death (44.4%). The number
of deaths from VL and the case fatality rate was higher in patients
$60 years (24.4%), followed by those within the age range 30–39
years (20.2%) (Table 3).
The results of univariate logistic regression analysis of the
demographic and clinical variables with respect of deaths from VL
are shown in Tables 4 and 5. The most significant non-adjusted
variables (p,0.05) associated with death were weakness, edema,
bleeding, other associated infections, jaundice, Leishmania-HIV co-
infection, Leishmania-tuberculosis co-infection, treatment with
amphotericin, treatment with pentavalent antimonial drug for 21
to 40 days, male gender, age range 30–39 years and $60 years.
The results of the multivariate logistic regression analysis of
those variables that were associated (p,0.25) with death from VL,
Table 1. Comparison between the variables of Windows and Net versions of the SINAN database.
Field Version Windows Version Net
Clinical manifestations (Yes, No, Unknow) Fever, weakness, emaciation, cough and/or
diarrhea, splenomegaly, hepatomegaly
Added variables: swelling, pallidness, other infections,
bleeding, jaundice and others manifestations
Co-infections (Yes, No, Unknow) HIV, tuberculosis, other types of infection HIV co-infection only
Date of the beginning of treatment Inexistent field Existing field
Diagnosis confirmation criteria (laboratory,
clinical-epidemiological)
Inexistent field Existing field
Evolution of the case Cure, death, unknown Cure, abandoned treatment, VL-death, death by other
causes, transfer (treatment interrupted in the original
municipality, but continued at some other location)
doi:10.1371/journal.pntd.0001511.t001
Table 2. Visceral leishmaniasis incidence and case fatality
rates, Belo Horizonte, Brazil, 2002–2009.
Year
VL Cases
a
(n)
Incidence
a,b
(per 100, habitants) Deaths
Case fatality
rate (%)
2002 77 3.4 9 11.7
2003 103 4.5 10 9.7
2004 134 5.8 25 18.7
2005 110 4.6 10 9.1
2006 128 5.3 12 9.4
2007 110 4.5 9 8.2
2008 161 6.6 20 12.4
2009 141 5.8 31 22.0
Total 964 ..
c 126 13.1
aCases obtained from the Municipality Health Service of Belo Horizonte/SINAN.
bPopulation data from Brazilian Institute of Geography and Statistics/IBGE.
cNumerical information not applicable.
doi:10.1371/journal.pntd.0001511.t002
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presented in Table 6. Model 1 (period 2002–2009) showed that
weakness, Leishmania-HIV co-infection and age $60 years were
associated with a greater chance of death. Model 2 (period 2007–
2009) revealed that variables included in the SINAN Net version,
such as other associated infections, bleeding and jaundice, were
significantly associated with the increased likelihood of deaths from
VL. It is important to emphasize that inclusion of the category
unknown in the multivariate logistic regression analysis had no
effect on the results generated by models 1 and 2, since the odds
ratio and the 95% CI values remained unchanged in either the
presence or absence of this category. The use of the category
unknown not only allowed a larger number of cases to be
considered in the final models but also improved the adjustment of
these models to the VL data as shown by the log likelihood and p
values.
Table 7 presents the predictive score, prepared from VL cases
notified between 2007 and 2009, for each of the four death-
associated factors revealed by Model 2. According to this system, a
score of 1 was attributed to the three variables (age $60 years,
bleeding and other associated infections), while a score of 2 was
attributed to the variable jaundice. The performance measures of
the predictive score were sensitivity (71.4%), specificity (73.7%),
positive and negative predictive values (28.9% and 94.5%) and the
area under the ROC curve (75.6%).
Discussion
In the present study, the factors associated with death from VL
were weakness, Leishmania-HIV co-infection, other associated
infections, bleeding, jaundice, and age $60 years. These findings
are in agreement with the Brazilian Ministry of Health [12,17,19]
in which factors associated with death from VL were considered to
be age ,6 months or .65 years, jaundice, bleeding and co-
morbidities including bacterial infections.
The records analyzed in the present study were obtained from a
database containing details of registered VL cases, each of which
would normally have been notified on clinical suspicion of the
disease. Our results reveal that it is possible to detect the factors
associated with death from VL at first clinical suspicion of the
disease and, hence, to identify the most vulnerable patients.
Timely application of specific and effective measures to the
patients would contribute greatly to a reduction in the lethality of
the disease. Several authors have suggested that knowledge
regarding the laboratory and clinical profiles of patients and their
association with death from VL could assist in the clinical
management and reduce lethality [4,12,17,19,24–26].
The case fatality rate registered in Belo Horizonte is one of the
highest in Brazil. Some hypotheses could explain the variation in
the rates as accessibility to the health service, suspicion of VL and
delayed diagnosis, treatment opportunity, clinical management of
the patient, toxicity of drugs, comorbities and Leishmania
population in circulation in Belo Horizonte. Considering the case
fatality rates in 2004 (18.7%) and 2009 (22.0%), it is possible that
the complex combination of these factors could contribute to the
unacceptable fatality rates during these years.
Factors associated with lethality from VL have been reported in
the literature [2,4,24–28]. A retrospective cohort study [26]
conducted in Recife (north-eastern Brazil) identified risk factors
associated with VL death in young patients (,15 years old) as
mucosal hemorrhage, jaundice, dyspnoea, bacterial infections,
reduced number of neutrophils and platelets. A case-control study
[4] conducted in Teresina (also in north-eastern Brazil) described
the occurrence of fever for more than 60 days, diarrhea, jaundice
and anemia as predictive factors for the death in VL patients.
Another case-control study performed in Teresina [25] confirmed
that bacterial infections and hemorrhage were the most relevant
factors associated with death from VL. However, a study performed
in Campo Grande (central westBrazil)identifiedbacterial infections
as the main cause of death among VL patients [24]. According to
Seaman et al [27], age $45 years, disease duration .5 months,
undernutrition and intense anemia were associated with an
increased risk of death from VL in Sudan. Following a study also
performed in Sudan, Collin et al [28] reported that the prognosis
factors for death were age ,2o r$45 years, disease duration .5
months, undernutrition, anemia, splenomegaly and, particularly,
episodes of diarrhea, vomit and bleeding.
The time interval between the onset of symptoms and time of
diagnosis was estimated and this interval was not significantly
associated with death from VL (Table 5). However, other studies
show the necessity to reduce delay in diagnosis and describe the
Table 3. Visceral leishmaniasis cases and fatality rate by age and sex, Belo Horizonte, Brazil, 2002–2009.
Age range
(years) Sex Total
Female Male
Cases Deaths
Case fatality
rate (%) Cases Deaths
Case fatality
rate (%) Cases Deaths
Case fatality
rate (%)
n% n% n%
0–4 112 31.9 9 8.0 120 22.4 11 9.2 232 26.1 20 8.6
5–9 56 16.0 3 5.4 54 10.1 7 13.0 110 12.4 10 9.1
10–19 38 10.8 1 2.6 51 9.5 2 3.9 89 10.0 3 3.4
20–29 40 11.4 3 7.5 70 13.0 13 18.6 110 12.4 16 14.6
30–39 23 6.6 4 17.4 71 13.2 15 21.1 94 10.6 19 20.2
40–49 36 10.3 6 16.7 69 12.9 8 11.6 105 11.8 14 13.3
50–59 21 6.0 3 14.3 41 7.6 5 12.2 62 7.0 8 12.9
$60 25 7.1 5 20.0 61 11.4 16 26.2 86 9.7 21 24.4
Total 351 100.0 34 9.7 537 100.0 77 14.3 888 100.0 111 12.5
doi:10.1371/journal.pntd.0001511.t003
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case outcome (cure or death). According to Kajaia et al [29], the
factors associated with VL relapse were delay in diagnosis for .90
days, haemoglobin level ,60 g/L and age ,1 year. In Tunisia
[30], children were evaluated and seven prognostic factors at the
time of hospital admission were identified: visit delayed .56 days,
fever lasting .21 days, normal or low temperature, hemorrhagic
syndrome, hemoglobin rate ,5.5 g/dL, sedimentation rate
,25 mm and hypoalbuminemia ,30 g/L. In Sudan [28], risk
factors for death among adults were age $45 years, malnutrition,
anemia and duration of illness $5 months. Also in Sudan [27], the
risk factors in adult patients were duration of illness $5 months,
age $45 years, hemoglobin level ,60 g/L, and body mass index
,12 kg/m
2.
The weakness, which is one of the earliest clinical symptoms of
VL, was found to be significantly associated with death. The most
likely explanation for this finding is that the study was based on
clinical manifestations presented by VL-suspect patients at their first
medical appointment. However, the early detection of weakness
may help to identify those patients presenting a higher likelihood of
an unsatisfactory evolution of their disease. A study conducted in
central west Brazil involving 55 individuals that had died from VL
described the occurrence of hyporexia (65.5%), asthenia (58.1%)
and adynamia (29.0%) [24]. It is probable that this set of conditions
formed part of the weakness reported by patients during anamnesis,
thus confirming the findings of the present study.
A VL-suspected case is defined as a patient presenting fever and
splenomegaly who originates from an Leishmania transmission area
or, if originating from an area in which transmission is absent,
where differential diagnosis has been discarded [12,17]. As
expected, there were high frequencies of patients in the study
population presenting either fever with splenomegaly (87.3%) or
fever with splenomegaly and hepatomegaly (83.0%), and the
frequencies were similar in death from VL and in cured patients.
Table 4. Demographic and clinical variables according to death from visceral leishmaniasis, Belo Horizonte, Brazil, 2002–2009.
Variables (n)
a Deaths from VL Odds Ratio 95% IC p values
No Yes
n% n %
Sex (n=888)
Female 317 40.8 34 30.6 1.0 ..
b ..
Male 460 59.2 77 69.4 1.6 1.0–2.4 0.04
Age range (years; n=888)
0–4 212 27.3 20 18.0 1.0 .. ..
5–9 100 12.9 10 9.0 1.1 0.5–2.4 0.89
10–19 86 11.1 3 2.7 0.4 0.1–1.3 0.12
20–29 94 12.1 16 14.4 1.8 0.9–3.6 0.10
30–39 75 9.7 19 17.1 2.7 1.4–5.3 0.00
40–49 91 11.7 14 12.6 1.6 0.8–3.4 0.19
50–59 54 6.9 8 7.2 1.6 0.7–3.8 0.31
$60 65 8.4 21 18.9 3.4 1.8–6.7 0.00
Clinical manifestation
Fever (n=860) 723 96.1 102 94.4 0.7 0.3–1.7 0.41
Splenomegaly (n=825) 642 89.0 92 88.5 0.9 0.5–1.8 0.86
Hepatomegaly (n=827) 607 84.0 88 84.6 1.1 0.6–1.9 0.86
Weakness (n=801) 568 81.3 95 93.1 3.1 1.4–6.9 0.01
Emaciation (n=783) 516 75.0 78 82.1 1.5 0.9–2.7 0.13
Cough (n=742) 319 48.9 50 55.6 1.3 0.8–2.0 0.24
Edema
(c) (n=240) 24 11.6 13 39.4 5.0 2.2–11.2 0.00
Pallidness
(c) (n=259) 149 66.2 28 82.4 2.4 0.9–6.0 0.07
Other infections
(3) (n=236) 44 21.8 19 55.9 4.6 2.1–9.7 0.00
Bleeding
(c) (n=238) 16 7.8 11 34.4 6.2 2.6–15.2 0.00
Jaundice
(c) (n=238) 13 6.3 14 43.8 11.6 4.7–28.3 0.00
Other manifestations
(c) (n=206) 55 31.1 7 24.1 0.7 0.3–1.8 0.45
Co-infection
HIV (n=553) 39 8.0 12 17.7 2.5 1.2–5.0 0.01
Tuberculosis
(d) (n=345) 9 2.9 4 10.5 3.9 1.1–13.3 0.03
aThe total number of individuals listed in SINAN and included in the study (Belo Horizonte, Brazil) were 888, of which 512 were registered in the Windows version and
376 in the Net version of the database.
bNumerical information not applicable.
cVariable registered for VL cases occurring in the period 2007–2009 (Net version of SINAN).
dVariable registered for VL cases occurring in the period 2002–2006 (Windows version of SINAN).
doi:10.1371/journal.pntd.0001511.t004
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(51.9%) of whom died from VL. The presence of jaundice
increased the chances of death from VL by a factor of 10
(ORadjusted 10.1; 95%CI 3.7–27.2). The large amplitude of the
confidence interval can be explained by the small number of
patients presenting jaundice. Following a study carried out in the
Brazilian State of Piauı ´ involving 12 deaths from VL and 78 cured
individuals, Werneck et al. [4] reported that the death-associated
factors were anemia, jaundice, fever for more than 60 days and
diarrhea. These authors pointed out that the last three symptoms
mentioned were identified at the first clinical examination and that
the presence of jaundice increased the chances of death by 10.6-
Table 5. Clinical variables according to death from visceral leishmaniasis, Belo Horizonte, Brazil, 2002–2009.
Deaths from VL Odds Ratio 95%IC p values
Variables (n)
a No Yes
n% n %
Time between the onset of symptoms and
notification (n=888; weeks)
up 4 441 56.8 54 48.7 1.0 ..
b ..
5–8 144 18.5 21 18.9 1.2 0.7–2.0 0.52
9–12 84 10.8 16 14.4 1.6 0.9–2.9 0.15
.12 108 13.9 20 18.0 1.5 0.9–2.6 0.14
Treatment
Initial drug administered (n=753)
Pentavalent antimonial (n=612) 570 84.8 42 51.9 1.0 .. ..
Amphotericin (n=135) 96 14.3 39 48.1 5.5 3.4–9.0 0.00
Pentamidine (n=6) 6 0.9 -
c -- - -
Duration of treatment with pentavalent
antimonial (n=354; days)
,20 (n=40) 32 9.8 8 30.8 1.0 .. ..
20 (n=55) 48 14.6 7 26.9 0.6 0.2–1.8 0.34
21–40 (n=251) 240 73.2 11 42.3 0.2 0.1–0.5 0.00
.40 (n=8) 8 2.4 - - - - -
Other drugs used following initial therapy failure (n=53)
Pentavalent antimonial (n=11) 10 21.7 1 14.3 1.0 .. ..
Amphotericin (n=41) 35 76.1 6 85.7 1.7 0.2–16.0 0.64
Pentamidine (n=1) 1 2.2 - - - - -
aThe total number of individuals listed in SINAN and included in the study were 888, of which 512 were registered in the Windows version and 376 in the Net version of
the database.
bNumerical information not applicable.
csymbol equal to zero.
doi:10.1371/journal.pntd.0001511.t005
Table 6. Factors associated with death from visceral leishmaniasis, Belo Horizonte, Brazil, 2002–2009.
Variables Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI) p values
Model 1 (n=888)
a
Weakness 3.1 (1.4–6.9) 2.9 (1.3–6.4) 0.01
Leishmania-HIV co-infection 2.5 (1.2–5.0) 2.4 (1.2–4.8) 0.02
Age ($60 versus,60 anos) 2.6 (1.5–4.4) 2.5 (1.5–4.3) 0.00
Model 2 (n=376)
b
Other infections 4.6 (2.1–9.7) 3.2 (1.3–7.8) 0,01
Bleeding 6.2 (2.6–15.2) 3.5 (1.2–10.3) 0.02
Jaudice 11.6 (4.7–28.3) 10.1 (3.7–27.2) 0.00
Age ($60 versus,60 anos) 2.6 (1.5–4.4) 3.1 (1.4–7.1) 0.02
aCovering the period 2002–2009 and including the variables present in both versions of SINAN (111 death from VL and 777 cures).
bCovering the period 2007–2009 and including the variables common to both versions of SINAN together with the new variables included in the Net version (49 death
from VL and 327 cures).
doi:10.1371/journal.pntd.0001511.t006
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conducted in the central west State of Mato Grosso do Sul,
jaundice was observed in 20.0% of patients who subsequently died
from VL [25]. It may be concluded that identification of jaundice
at the first examination or during a later follow is a valuable
predictor of VL patients likely to present a negative prognosis.
The occurrence of jaundice may indicate liver damage [25]
which, in some cases of VL, has been observed in the form of a
massive necrotic destruction of the organ [31,32]. Moderate
alterations of hepatic function, together with thrombocytopenia,
may give rise to serious hemorrhagic processes [27]. A study of
clinical and laboratory data relating to 55 patients who had died
from VL revealed increased levels of albumin and aspartate
aminotransferase at the time of admission to hospital, and high
levels of creatinine and amylase prior to death [24]. According to
Jeronimo et al. [10], increased levels of liver enzymes in untreated
patients presenting a profile of jaundice at the time of admission to
hospital, may signal the presence of hepatitis by Leishmania
infection.
In the present study, the ages of cured patients varied from 3 to
93 years old whereas the ages of those who had died from VL were
between 5 months and 86 years. The lethality in older individuals
($60 years) was the highest (24.4%), a value similar to that
reported by Oliveira et al. [24] for elderly subjects. In Sudan [27],
age $45 years old was associated with an increased risk of death
from VL. It is expected that older VL patients would present a
higher risk of mortality for many reasons, e.g. cardiovascular
diseases that may coexist with leishmaniasis. Additionally,
although N-methyl glucamine antimoniate constitutes the first
choice treatment for VL, the drug may have side effects including
severe cardiac arrhythmia. This medication was prescribed for 50
of the patients aged $60 years included in the present study, and
seven (14.0%) of these died. However, other studies [25,28]
associated a higher risk of death with those of a younger age. In
Uganda [33], the main risk factors for in-hospital death identified
were age ,6 years and .15 years, concomitant tuberculosis or
hepatopathy, and drug-related adverse events. The case fatality
rate among patients .45 years of age was strikingly high (29.0%).
Multivariate regression analysis models 1 and 2 identified age of
$60 years as a factor associated with death from VL (OR 2.5 and
3.1, respectively). It is worth noting that the present study involved
86 patients aged $60 years and of these 21 died from VL
accounting for 19.0% of the total deaths analyzed. However, in
2009, the Brazilian Ministry of Health mentioned that VL patients
aged ,1 and .40 years were at greater risk [12], and more
recently, Costa et al. [25] described that individuals in these two
age ranges are the most vulnerable to death from VL.
In this study, 63 subjects presented other associated infections
with significantly difference between the cured patients (n=44;
5.7%) and those that died from VL (n=19; 17.1%) Multivariate
logistic regression analysis showed that the occurrence of other
infections increased the chances of death by 3-fold. A recent study
involving 55 hospitalized VL patients who progressed to death
found that 65.5% had been diagnosed with other infections, most
commonly sepsis (66.7%) and pneumonia (63.9%), at the time of
admission and during hospitalization [24]. The most likely
explanation for such a high frequency of co-infection is that all
of the studied patients were hospitalized and could be evaluated at
the time of admission and throughout hospitalization. Patients
with VL are characteristically neutropenic and, therefore, present
reduced inflammatory response and are at increased risk from
other established or concealed infections [34]. This type of
physiopathological mechanism may explain the inclusion of other
infections among the prognosis factors for death from VL.
Twenty-seven individuals presented history of bleeding at the
first clinical examination with frequencies that were significantly
different between the 16 cured patients (2.1%) and the 11 deaths
from VL (9.9%). The presence of bleeding increased the chances
of death by 3.5-fold. Oliveira et al. [24] recently reported the
occurrence of bleeding in 32.7% of deaths from VL. Infection and
hemorrhage are classical complications of VL [4,12,19,24,25] and,
in the present study, were recorded in 19 and 11 deaths,
respectively. Twelve patients were affected by both complications,
and of these six (50.0%) died from VL. In a case-control study,
Werneck et al. [4] showed that all of the cases of death from VL
presented infectious or hemorrhagic complications, while Costa et
al. [25] reported that these conditions represented the two most
relevant factors associated with death from VL. Hemorrhagic
phenomena are probably associated with disseminated intravas-
cular coagulation [35], i.e. the activation of coagulation and
fibrinolysis that is initiated as part of the inflammatory response by
a mechanism similar to that established for sepsis [36].
Following a study of Tunisian children affected from VL, it was
reported that bleeding and a period of more than 56 days between
the onset symptoms and the first clinical examination were among
the seven most important factors associated with a negative
prognosis [30]. In the present study, however, the time between
the onset of symptoms and clinical suspicion of VL showed no
such association.
According to univariate analysis, Leishmania-HIV and Leishmania-
tuberculosis co-infections were both significantly (p,0.05) associ-
ated with death from VL. However, in the multivariate analysis
only co-infection with HIV was significantly correlated with death
(ORadjusted 2.4; 95% CI 1.2–4.8). Leishmania-HIV co-infection is
an emerging problem that requires urgent attention since, in
recent years, VL has become an opportunistic disease in HIV-
infected subjects. Indeed, VL may recur many times in HIV-
infected patients regardless of the provision of adequate treatment,
and the outcome is often fatal [37–40]. Moreover, the presence of
VL accelerates the progression of HIV by promoting viral
replication and aggravating the status of immunosuppression
[40]. Additionally, it has been observed in vitro that HIV induces
the replication of Leishmania by reducing T cells that are able to
recognize Leishmania antigens. According to Cruz et al. [41], HIV
may invade and replicate within Leishmania-bearing macrophages
even though TCD4
+ are the preferred cells. Thus, both pathogens
can act in synergism and aggravate the condition of a co-infected
patient [42].
In a study conducted in north-eastern Brazil involving a
chronological serie of hospital records during a period of 10 years
(1996–2005) and relating to 396 VL-patients (76 deaths and 320
cured patients), nine Leishmania-HIV co-infected individuals were
identified and six of these progressed to death [25]. The authors
suggested that increased lethality with co-infection could be
Table 7. Predictive scoring system for death from visceral
leishmaniasis, Belo Horizonte, Brazil, 2007–2009.
Prognosis factor Regression Coeficient Score
Other infections 1.17 1
Bleeding 1.25 1
Jaundice 2.31 2
Age ($60 versus,60 years) 1.13 1
Scoring system based on the variables listed in the SINAN Net version.
doi:10.1371/journal.pntd.0001511.t007
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occurrence of other opportunistic infections. The available
evidence clearly indicates that VL patients should be tested for
HIV, and co-infected individuals should receive special care
[12,19,37].
Regarding the initial drug used in treatment (Table 5), it can be
observed that the fatality rate was 6.9% (42/612) for those patients
treated with Pentavalent Antimonial. Among those who received
Amphotericin, the case fatality rate was 28.9% (39/135). This
difference demonstrated by univariate logistic regression analysis
can be explained by the fact that in Brazil, the pentavalent
antimonials are the drugs of choice for treatment of VL due to its
proven therapeutic efficacy. Amphotericin is recommend as the
first choice in patients six months or under and for those over 65
years old and those with severe clinical manifestation such as:
malnutrition, comorbidities (which include bacterial infection),
jaundice, hemorrhagic phenomena (except epistaxis), generalized
edema, signs of toxemia (lethargy, poor perfusion, cyanosis,
tachycardia or bradycardia, hypoventilation or hyperventilation,
and hemodynamic instability) [19].
Measures that have been applied to control the canine reservoir
and the insect vector have not been successful in preventing the
spread of VL in Brazil, and early diagnose and treatment of
human cases remain the main approaches for reducing lethality.
Guidelines published by the Brazilian Ministry of Health stress the
key factors associated with death from VL with the aim of ensuring
that patients who require special care can be identified and
classified according to severity of risk [12,19]. While the results
obtained in the present study support these definitions, in order to
reduce death from VL it is necessary first to identify the prognosis
factors and then to adopt the correct clinical strategies. As stated
by Werneck et al. [4], the key challenge lies in making the correct
medical decisions following the identification of high-risk patients.
The prognostic score generated in the present study is based on
four clinical variables (age$60 years, bleeding, other associated
infections and jaundice). The predictive performance of this score
was: sensitivity 71.4%, specificity 73.7%, positive and negative
predictive value (28.9% and 94.5%) and area under the ROC
curve (75.6%). The predictive performance could be improved
with addition of laboratory variables according to other studies
carried out in Brazil [4,26]. However, these laboratory variables
are unavailable in SINAN. The advantage of the system developed
herein is its simplicity because it was based on patient age and
clinical symptoms at the clinical suspicious. Additionally, decisions
regarding the clinical management of VL patients can be
facilitated by the identification of either a distinct prognosis factor
or a combination of factors. However, further studies that advance
our understanding of the factors associated with moderate and
severe forms of VL are also necessary. Furthermore, it is
particularly important to validate the applicability of the score in
immunosuppressed VL individuals.
The key issue, however, is to define a simple prognosis score
that could be applied in basic health units and would allow the
early detection of VL cases for redirection to specialized health
service. For the purposes of comparison, patients attaining a
predictive score in the range from 1 to 5 received an allocated
score of 1, while those presenting none of the death prognosis
factors received an allocated score of 0. The scoring system
presented here can be used to identify patients running a higher
risk of death from VL at the time of clinical suspicion. Those
patients with a score between 1 and 5 should receive specialized
clinical management during treatment.
Our study had limitations that deserve to be discussed. The
multivariate analyses did not take into account all possible
factors that could contribute to unfavorable evolution of the VL
case, e.g. nutritional status, the presence of other comorbidities
(not included here as autoimmune diseases, alcoholism, and
other drug abuse). These variables are not collected through the
SINAN system. It is noteworthy that this study was designed to
assess whether the variables in the SINAN could be useful in
identifying patients facing a higher risk of death from VL at
moment of clinical suspicion. However, we consider of great
importance further studies designed to include, in addition to the
SINAN database, clinical and laboratory variables of VL
patients.
Another limitation of this study is related to the validation of the
prognostic scoring system which was proposed using the same
patients whose data was used in its preparation (patients in the
period 2007–2009). In fact, as this score included the variables of
the newer version of SINAN, there is until now no distinct set of
patients for validation. In the future, we intend to validate this
prognostic scoring system using several random samples from the
SINAN database.
In order to improve the quality of assistance, the Brazilian
Ministry of Health [12,17,19] has urged local surveillance
authorities to provide infrastructure to the basic health units and
to encourage the training of the professionals to organize
comprehensive support to the patients with efficiency. Moreover,
the flow of VL patients through specialized reference service and
other health units must be established and disclosed. Some
researchers have further suggested that VL-lethality could be
greatly reduced by speeding up laboratory diagnosis and
developing less toxic alternative drugs [24].
In Brazil, suspected VL cases must be notified to the health
authorities using the appropriate SINAN epidemiological form.
All fields in the form must be completed even in the absence of
information (missing code). However, some of the variables
(schooling, occupation, ethnicity, weight, date of the start of
treatment and relapse) could not be evaluated in the present study
because the corresponding fields had high proportion of missing
data. It would have been helpful to know the date of the start of
treatment, since early diagnosis and treatment of VL are
important in reducing the lethality of the disease. Indeed, the
absence of vital information in partially completed medical records
is a chronic problem in Brazil [43].
SINAN has a specific module for VL which includes the
registration of the variables described in the literature associated
with the disease. In Brazil, the Epidemiological Surveillance
Service works in conjunction with other information systems such
as Mortality Information System (SIM). So it is routine for this
service to verify if deaths from reportable diseases such as VL are
listed in SINAN system. Of course, there may be some
underreporting due to the difficulty in defining the VL clinical
case or identifying the VL as cause of death. Therefore,
underreporting is minimized by comparing the two systems
mentioned.
This study may provide ammunition to the debate on the
usefulness and limitations of the Reportable Disease Information
System (SINAN) database. According to the World Health
Organization [2], improvement in the flow of information is one
of the main challenges in the control of tropical neglected
diseases.
This study has identified vulnerable patients who are at higher
risk of death from VL and who would benefit from early predictive
evaluation of the prognostic. In conclusion the knowledge
regarding the factors associated with death may contribute for
clinical management and reduction of lethality from VL.
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